What is claimed is:

1. Use of an interleukin-4 receptor (IL-4R) antagonist in the manufacture of a medicament for the treatment of atopic dermatitis (AD) or the improvement of an AD-associated parameter in a subject having moderate-to-severe AD, wherein the subject is ≥6 years to <12 years of age; wherein the AD-associated parameter is selected from the group consisting of Investigators Global Assessment (IGA), Body Surface Area Involvement of Atopic Dermatitis (BSA), Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), 5-D Pruritus Scale, Pruritus Numeric Rating Scale (NRS), Patient Global Impression of Disease, Patient Global Impression of Change, Children's Dermatology Life Quality Index (CDLQI), Patient Oriented Eczema Measure (POEM), Dermatitis Family Index (DFI) score, Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety score, and PROMIS depression score;

wherein an initial dose followed by one or more doses of the IL-4R antagonist are to be subcutaneously administered to the subject, wherein the IL-4R antagonist is dupilumab; and

for a subject having a body weight of <30 kg, the IL-4R antagonist is to be administered at an initial dose of 600 mg followed by one or more secondary doses of 300 mg every four weeks (Q4W).

2. Use of an interleukin-4 receptor (IL-4R) antagonist in the manufacture of a medicament for the treatment of atopic dermatitis (AD) or the improvement of an AD-associated parameter in a subject having moderate-to-severe AD, wherein the subject is ≥6 years to <12 years of age; wherein the AD-associated parameter is selected from the group consisting of Investigators Global Assessment (IGA), Body Surface Area Involvement of Atopic Dermatitis (BSA), Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), 5-D Pruritus Scale, Pruritus Numeric Rating Scale (NRS), Patient Global Impression of Disease, Patient Global Impression of Change, Children's Dermatology Life Quality Index (CDLQI), Patient Oriented Eczema Measure (POEM), Dermatitis Family Index (DFI) score, Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety score, and PROMIS depression score;

wherein an initial dose followed by one or more doses of the IL-4R antagonist are to be subcutaneously administered to the subject, wherein the IL-4R antagonist is dupilumab; and

for a subject having a body weight of ≥30 kg to <60 kg, the IL-4R antagonist is to be administered at an initial dose of 400 mg followed by one or more secondary doses of 200 mg every two weeks (Q2W).

3. Use of an interleukin-4 receptor (IL-4R) antagonist in the manufacture of a medicament for the treatment of atopic dermatitis (AD) or the improvement of an AD-associated parameter in a subject having moderate-to-severe AD, wherein the subject is ≥6 years to <12 years of age; wherein the AD-associated parameter is selected from the group consisting of Investigators Global Assessment (IGA), Body Surface Area Involvement of Atopic Dermatitis (BSA), Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), 5-D Pruritus Scale, Pruritus Numeric Rating Scale (NRS), Patient Global Impression of Disease, Patient Global Impression of Change, Children's Dermatology Life Quality Index (CDLQI), Patient Oriented Eczema Measure (POEM), Dermatitis Family Index (DFI) score, Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety score, and PROMIS depression score;

wherein an initial dose followed by one or more doses of the IL-4R antagonist are to be subcutaneously administered to the subject, wherein the IL-4R antagonist is dupilumab; and

for a subject having a body weight of ≥60 kg, the IL-4R antagonist is to be administered at an initial dose of 600 mg followed by one or more secondary doses of 300 mg Q2W.

4. The use according to any one of claims 1-3, wherein the subject is a subject with moderate-to-severe AD that is not adequately controlled with topical AD medications or for whom topical treatment is medically inadvisable.

5. The use according to any one of claims 1-3, wherein the subject is a subject with severe AD that is not adequately controlled with topical AD medications or for whom topical treatment is medically inadvisable.

6. The use according to claim 5, wherein the subject is inadequately responsive to treatment with a topical corticosteroid (TCS).

7. The use according to any one of claims 1-4, wherein the subject is a subject with moderate-to-severe AD who is a candidate for systemic therapy.

8. The use according to any one of claims 1-3, 5, and 6, wherein the subject is a subject with severe AD who is a candidate for systemic therapy.

9. The use according to any one of claims 1-3, 5, and 6, wherein the subject:

(i) has a baseline IGA score = 4;

(ii) has a baseline EASI score ≥ 21;

(iii) has a baseline BSA affected by AD ≥ 15%; and/or

(iv) has chronic AD diagnosed at least one year prior to the onset of treatment.

10. The use according to claim 1, wherein the subject has a body weight of ≥15 kg to <30 kg.

11. The use according to any one of claims 1 to 10, wherein the IL-4R antagonist is to be administered in combination with a TCS.

12. The use according to claim 11, wherein the TCS is a medium-potency TCS.

13. The use according to claim 11, wherein the TCS is a low-potency TCS.

14. The use according to any one of claims 1 to 13, wherein treatment with the IL-4R antagonist results in an improvement of an AD-associated parameter that is selected from:

(i) a reduction from baseline in IGA score to achieve an IGA score of 0 or 1 by week 16 after the first dose of the antagonist is to be administered; and

(ii) a reduction of at least 75% from baseline in an EASI score (EASI-75) by week 16 after the first dose of the antagonist is to be administered.

15. The use according to any of claims 1 to 14, wherein the IL-4R antagonist is contained in a container selected from the group consisting of a glass vial, a syringe, a pre-filled syringe, a pen delivery device, and an autoinjector.

16. The use according to claim 15, wherein the IL-4R antagonist is contained in a pre-filled syringe.

17. The use according to claim 16, wherein the pre-filled syringe is a single-dose pre-filled syringe.

18. The use according to claim 15, wherein the IL-4R antagonist is contained in an autoinjector.

19. The use according to claim 15, wherein IL-4R antagonist is contained in a pen delivery device.